A Phase 2, Multicenter, Double-Blind, Randomized, Controlled Trial of the Safety and Immunogenicity of a Self-Amplifying mRNA COVID-19 Vaccine in Adult Hematopoietic Cell Transplant Recipients
Latest Information Update: 10 Feb 2026
At a glance
- Drugs ARCT 021 (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
Most Recent Events
- 10 Feb 2026 New trial record